co.don AG 

(Public, ETR:CNW)   Watch this stock   
Find more results for CNW
Oct 15, 2009
Q3 2009 CODON AG Earnings Release
  

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -72.05% -57.01%
Operating margin -71.20% -65.78%
EBITD margin - -58.74%
Return on average assets -30.90% -19.57%
Return on average equity -36.97% -23.15%
Employees 29 -

Address

Warthestrasse 21
Teltow, 14513
Germany
+49-3328-43460 (Phone)
+49-3328-434649 (Fax)

Website links

co.don AG discussions

  View all discussions »

Description

co.don AG is a Germany-based company active in the tissue engineering field of regenerative medicine. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. They include co.don chondrotransplant that is used for cartilage treatment, particularly in the knee area; co.don chondrosphere, which is three-dimensional articular cartilage cultivated outside of the body; co.don chondrotransplant DISC applied for the regeneration of intervertebral discs, and co.don osteotransplant DENT that is an autologous bone cell transplant for dental applications. On March 11, 2008, co.don AG established its wholly owned subsidiary, co.don schweiz gmbh that is responsible for marketing of the Company’s products on the Swiss market.

Officers and directors

Gert Weidl
Chairman of the Supervisory Board
Andreas Baltrusch
Chairman of the Management Board, Chief Executive Officer
Thommy Staehlin
Vice Chairman of the Supervisory Board
Vilma Siodla
Member of the Management Board
Gerhart Eugen Hanhart
Member of the Supervisory Board